Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Vulcan Value Partners Talks Oracle (ORCL)’s Value, Plus New Positions in McKesson (MCK), Qorvo (QRVO), More

Page 1 of 2

Vulcan Value Partners, Llc is a Birmingham-based hedge fund. The fund invests in publicly-traded companies using a long-term investment horizon. The fund also tries to identify stocks which are trading at significant discounts in comparison to their intrinsic value. The fund has a public equity portfolio containing holdings valued at $10.89 billion as of September 30, with 27% of that value being invested in stocks from the Information Technology sector, followed by 24% in the Finance sector.

In this article we will look at the fund’s positions in Oracle Corporation (NASDAQ:ORCL), McKesson Corporation (NYSE:MCK), UnitedHealth Group Inc. (NYSE:UNH), Qorvo Inc (NASDAQ:QRVO), and Dover Corp (NYSE:DOV), as well as its comments on some of those positions from its third-quarter investor letter.

We follow over 700 hedge funds and other institutional investors and by analyzing their quarterly 13F filings, we identify stocks that they are collectively bullish on and develop investment strategies based on this data. One strategy that outperformed the market over the last year involves selecting the 100 best-performing funds and identifying the 30 mid-cap stocks that they are collectively the most bullish on. Over the past year, this strategy generated returns of 18%, topping the 8% gain registered by S&P 500 ETFs.

Oracle ORCL

Ken Wolter/shutterstock.com

Oracle Corporation (NASDAQ:ORCL)

– Shares Owned by Vulcan Value Partners (as of September 30): 22.33 million

– Value of Vulcan Value Partners’ Holding (as of September 30): $877.29 million

Vulcan Value Partners’ largest holding is in Oracle Corporation (NASDAQ:ORCL), despite reducing its stake in the stock by 3% during Q3, to 22.33 million shares worth $877.29 million. According to Vulcan Value Partners, its high customer retention rate of 90% makes Oracle intriguing. The company’s contract for licensing agreements takes care of inflation, which makes it lot like quality REITs. The company can, however, add more services in cloud computing and look to acquire more customers. Vulcan Value Partners expects Oracle to grow its bottom-line by 8%. Also, having net cash on its balance sheet means that the company can grow two-times faster than an REIT without any leverage. Oracle trades at 11.5-times free cash flow while the return on its cash flow is 8.8%.

The company recently announced the completion of its acquisition of NetSuite Inc (NYSE:N) for $9.3 billion in cash. Overall, 53% of the latter’s shares were tendered. This is the second-biggest acquisition for the company, trailing only its PeopleSoft purchase for $10.3 billion in 2005. Oracle was forced to change its strategy due to tough competition from rivals like salesforce.com for enterprise services. The acquisition will help the company reach small clients like mid-market enterprises, which is an area where Oracle Corporation (NYSE:ORCL) has struggled to make its presence felt.

Follow Oracle Corp (NYSE:ORCL)
Trade (NYSE:ORCL) Now!

McKesson Corporation (NYSE:MCK)

– Shares Owned by Vulcan Value Partners (as of September 30): 1.69 million

– Value of Vulcan Value Partners’ Holding (as of September 30): $281.09 million

Vulcan Value Partners added a new position in medical supplies and healthcare information technology company McKesson Corporation (NYSE:MCK) to its portfolio during Q3. The fund bought 1.69 million shares of the company during the quarter, valued at $281.09 million at the end of the period. McKesson reported lower-than-expected third-quarter results recently, as the company reported EPS of $2.94 and revenue of $50 billion, missing estimates by $0.11 per share and $1.2 billion respectively. The company also slashed its fiscal year 2017 EPS forecast to $12.35-$12.85 from the previous range of $13.43-$13.93. That pushed it well below the Street’s estimate of $13.59. Vulcan Value likes McKesson because of the high barrier of entry in its industry.

Follow Mckesson Corp (NYSE:MCK)
Trade (NYSE:MCK) Now!

On the next page we’ll look at the fund’s thoughts and activity as it related to UnitedHealth Group Inc. (NYSE:UNH), Qorvo Inc (NASDAQ:QRVO), and Dover Corp (NYSE:DOV).

Page 1 of 2
Loading Comments...